ATE359072T1 - Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen - Google Patents

Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen

Info

Publication number
ATE359072T1
ATE359072T1 AT00900110T AT00900110T ATE359072T1 AT E359072 T1 ATE359072 T1 AT E359072T1 AT 00900110 T AT00900110 T AT 00900110T AT 00900110 T AT00900110 T AT 00900110T AT E359072 T1 ATE359072 T1 AT E359072T1
Authority
AT
Austria
Prior art keywords
composition
melatonin
related conditions
antihypertensive drugs
treating resistance
Prior art date
Application number
AT00900110T
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of ATE359072T1 publication Critical patent/ATE359072T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Indole Compounds (AREA)
AT00900110T 2000-01-05 2000-01-05 Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen ATE359072T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000009 WO2001049286A1 (en) 2000-01-05 2000-01-05 Method and formulation for treating resistance to antihypertensives and related conditions

Publications (1)

Publication Number Publication Date
ATE359072T1 true ATE359072T1 (de) 2007-05-15

Family

ID=11042938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00900110T ATE359072T1 (de) 2000-01-05 2000-01-05 Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen

Country Status (31)

Country Link
US (3) US7332177B1 (de)
EP (1) EP1272177B1 (de)
JP (1) JP4996803B2 (de)
CN (1) CN1414851A (de)
AT (1) ATE359072T1 (de)
AU (1) AU782266B2 (de)
BG (1) BG65637B1 (de)
BR (1) BR0016918A (de)
CA (1) CA2396129C (de)
CY (2) CY1108018T1 (de)
CZ (1) CZ299931B6 (de)
DE (1) DE60034373T2 (de)
DK (1) DK1272177T3 (de)
EA (1) EA004679B1 (de)
EE (1) EE200200379A (de)
ES (1) ES2284471T3 (de)
HK (1) HK1052655A1 (de)
HU (1) HU227002B1 (de)
IL (1) IL150190A0 (de)
IS (1) IS6439A (de)
MX (1) MXPA02005783A (de)
NO (1) NO322567B1 (de)
NZ (1) NZ520078A (de)
PL (1) PL201219B1 (de)
PT (1) PT1272177E (de)
SI (1) SI1272177T1 (de)
SK (1) SK287508B6 (de)
TR (1) TR200201724T2 (de)
TW (1) TWI260983B (de)
UA (1) UA77394C2 (de)
WO (1) WO2001049286A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
AU2011323805A1 (en) * 2010-10-25 2013-05-23 Uico, Inc. Control system with solid state touch sensor for complex surface geometry
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP3500163A1 (de) * 2016-08-18 2019-06-26 Koninklijke Philips N.V. Blutdruckverwaltung
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
ES2724933A1 (es) * 2018-03-13 2019-09-17 Ocupharm Diagnostics Sl Terapia combinada con melatonina para la reducción de la presión intraocular
GB2617102A (en) * 2022-03-29 2023-10-04 John Hemming Trading Ltd Sleep therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin
US5646049A (en) 1992-03-27 1997-07-08 Abbott Laboratories Scheduling operation of an automated analytical system
SG41955A1 (en) 1992-04-07 1997-08-15 Neurim Pharma 1991 Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
WO1995002068A1 (fr) 1993-07-09 1995-01-19 Wakunaga Seiyaku Kabushiki Kaisha Methode de discrimination des acides nucleiques et necessaire d'essai a cette fin
SK284521B6 (sk) 1995-02-01 2005-05-05 Neurim Pharmaceuticals (1991) Ltd. Použitie melatonínu na prípravu farmaceutického prostriedku
US5648727A (en) 1995-10-24 1997-07-15 Dpc Cirrus Inc. Capacitive level sensing pipette probe
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
US5849338A (en) * 1996-04-10 1998-12-15 Chronorx Llc Unit dosage forms for treatment of vasoconstriction and related conditions
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии

Also Published As

Publication number Publication date
CA2396129A1 (en) 2001-07-12
NO322567B1 (no) 2006-10-30
HUP0204089A3 (en) 2005-12-28
US20120070501A1 (en) 2012-03-22
SI1272177T1 (sl) 2007-10-31
US20080085317A1 (en) 2008-04-10
DE60034373T2 (de) 2007-12-20
NZ520078A (en) 2004-02-27
SK9732002A3 (en) 2002-11-06
CY2007033I2 (el) 2009-11-04
US7332177B1 (en) 2008-02-19
AU782266B2 (en) 2005-07-14
JP2003519181A (ja) 2003-06-17
MXPA02005783A (es) 2003-10-14
EE200200379A (et) 2003-10-15
UA77394C2 (uk) 2006-12-15
EP1272177A4 (de) 2004-04-28
DK1272177T3 (da) 2007-08-06
WO2001049286A1 (en) 2001-07-12
IL150190A0 (en) 2002-12-01
EP1272177A1 (de) 2003-01-08
TR200201724T2 (tr) 2003-03-21
EA004679B1 (ru) 2004-06-24
BG65637B1 (bg) 2009-04-30
ES2284471T3 (es) 2007-11-16
HUP0204089A2 (hu) 2003-04-28
US8075914B2 (en) 2011-12-13
HU227002B1 (en) 2010-04-28
TWI260983B (en) 2006-09-01
CY2007033I1 (el) 2009-11-04
DE60034373D1 (de) 2007-05-24
NO20023102L (no) 2002-08-30
BR0016918A (pt) 2004-03-23
CN1414851A (zh) 2003-04-30
SK287508B6 (sk) 2010-12-07
PL201219B1 (pl) 2009-03-31
AU1888200A (en) 2001-07-16
PT1272177E (pt) 2007-07-11
CA2396129C (en) 2010-11-30
BG106978A (en) 2003-03-31
IS6439A (is) 2002-06-24
HK1052655A1 (zh) 2003-09-26
PL356325A1 (en) 2004-06-28
US8728511B2 (en) 2014-05-20
JP4996803B2 (ja) 2012-08-08
CZ299931B6 (cs) 2008-12-29
EP1272177B1 (de) 2007-04-11
CZ20022346A3 (cs) 2002-11-13
EA200200738A1 (ru) 2002-12-26
NO20023102D0 (no) 2002-06-27
CY1108018T1 (el) 2011-04-06

Similar Documents

Publication Publication Date Title
ATE359072T1 (de) Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
DE60118547D1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE418558T1 (de) Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems
DE60323876D1 (de) Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
BR0003648A (pt) Composições e métodos para tratar condições alérgicas e inflamatórias com tosse
NO20030483D0 (no) Assosiasjoner av dalfopristin/quinupristin med cefpirom
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
DE60308127D1 (de) Pharmazeutische Zusammentsetzung zur medizinischen Behandlung von gutartiger prostathyperplasie, dessen Vorbereitungsmethode und dessen therapeutische Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272177

Country of ref document: EP